FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to multivalent compounds which bind programmed death ligand 1 (PD-L1), which are administered to a mammal with a malignant growth for treating a mammal. In some cases, the multivalent PD-L1-binding compound can include two or more polypeptides of programmed death protein 1 (PD-1) (and/or fragments thereof, capable of binding to PD-L1).
EFFECT: invention makes it possible to increase efficiency of PD-1 for neutralization of PD-L1 present on PD-L1-positive malignant cells in therapy of malignant neoplasms.
12 cl, 20 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| IMMUNOGLOBULIN WITH TANDEM FAB- FRAGMENTS AND ITS APPLICATION OPTIONS | 2017 |
|
RU2767329C2 |
